ONCO — Onconetix, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1782107 ·
Last close
$0.99
Market Cap
$3.67M
52W High
$67.30
52W Low
$0.91
ADV30
1,257,467
Next earnings
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 21,457 -1,655 -2,091,801 -4,214,875 14,832,086 3,716,072 3,083,885
Dec 2025 303,596 247,684 -1,281,367 5,669,687 24,926,638 5,220,654 9,160,287
Sep 2025 303,651 268,894 -2,069,242 -8,783,702 19,678,868 836,556 16,303,023
Jun 2025 106,494 70,503 -1,341,418 -2,372,442 19,119,036 283,515 13,209,275

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,800,191
Investing CF
$0
Financing CF
$12,214,220
CapEx
$-6,187
Dividends Paid
Buybacks
$-395,933
EPS Diluted TTM
$-2890.10
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-135,429,433
Inventory
$137,642
Receivables
$100,063
ST Investments
EBIT TTM
$-9,171,150
Pretax Income TTM
$-9,700,807
Interest Exp TTM
$529,657
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$735,198
EBITDA
$-6,768,008
Free Cash Flow
$-6,337,745
Enterprise Value
$-2,187,976
Total Cash
$3,716,072
Total Debt
$289,922
Shares Out
3,691,492
Trailing EPS
$1377.40
Book Value
$4.26
ROE
-123.3%
ROA
-25.2%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 815,371 -6,344,856 -14,032,342 24,926,638 9,160,287 -9,678,390
Dec 2024 2,524,116 -10,331,243 -58,691,023 28,181,563 18,571,008 -10,495,816
Dec 2023 58,465 -17,847,249 -37,409,694 87,518,032 86,113,556 -13,581,018
Dec 2022 0 -13,481,240 -13,419,830 26,310,447 3,922,445 -8,675,534
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.85

Peers — same industry

TickerNameMarket CapLastDaily %
XRTX XORTX Therapeutics Inc. $3.72M $2.15
ACUT Accustem Sciences Inc. $3.72M $0.23
CVSI CV Sciences, Inc. $3.77M $0.02
PPCB Propanc Biopharma, Inc. $3.90M $1.71
NXTS Nexentis Technologies Inc. $3.90M $5.34

News headlines (Yahoo Finance, 1h cache)

Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
2026-05-19 12:00 · Yahoo
Realbotix Provides Update on Nasdaq Listing
2026-05-19 11:30 · Yahoo
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
2026-05-13 13:25 · Yahoo
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
2026-04-17 23:00 · Yahoo
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
2026-04-09 12:30 · Yahoo
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
2026-04-07 22:00 · Yahoo
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
2026-04-02 12:30 · Yahoo
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
2026-03-31 12:30 · Yahoo
BC-Most Active Stocks
2026-03-27 14:30 · Yahoo
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
2026-03-25 16:47 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.